Investor Relations Home
|IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market.|
The Company was incorporated in California in February 1989 as IRIS Medical Instruments, Inc. In November 1995, we changed our name to IRIDEX Corporation and reincorporated in Delaware. Investors and others should note that we announce material financial information to our investors using SEC filings, press releases, our investor relations website, public conference calls and webcasts. We use these channels as well as social media to communicate with investors, customers and the public about our company, our products and other issues. It is possible that the information we post on social media channels could be deemed to be material information. We encourage investors, our customers, and others interested in our company to review the information we post on our Facebook page (www.facebook.com/IRIDEX) and Twitter feed (https://twitter.com/IRIDEX).
|01/09/17||IRIDEX Announces Preliminary Unaudited Revenues for 2016 Fourth Quarter and Full Year|
|MOUNTAIN VIEW, Calif., Jan. 9, 2017 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported preliminary revenues of approximately $12.4 to $12.5 million and $46.0 to $46.1 million for the fourth quarter and full year 2016, respectively, meeting the previously provided quarterly and full year guidance provided by the Company. Revenue growth compared to fourth quarter and full year 2015 was driven by the Company's new flagship Cyclo G6™ glaucoma laser platform that is powered b... |
|12/09/16||IRIDEX Corporation Prices Public Offering of Common Stock|
|MOUNTAIN VIEW, Calif., Dec. 9, 2016 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced the pricing of its underwritten public offering of an aggregate of 1.15 million shares of common stock at a price of $14.00 per share, $0.01 par value (the "Offering" with such shares being the "Shares"). IRIDEX expects to receive gross proceeds of $16.1 million, before deducting underwriting discounts and other estimated offering expenses. IRIDEX has also granted the underwriters a 3... |
|12/08/16||IRIDEX Corporation Announces Proposed Public Offering of Common Stock|
|MOUNTAIN VIEW, Calif., Dec. 8, 2016 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it intends to offer newly issued shares of common stock, $0.01 par value (the "Offering" with such shares being the "Shares") pursuant to an underwritten public offering. The final terms of the Offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the Offering may be completed.
IRIDEX expects to use the net... |
|11/07/16||IRIDEX to Present at Upcoming Investor Conferences|
|MOUNTAIN VIEW, Calif., Nov. 7, 2016 /PRNewswire/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that management is scheduled to present at the following investor conferences in New York City:
The Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 17, 2016, at 8:00 am ET.
The Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016, at 11:50 a.m. ET.
Live audio webcasts of the presentations may be accessed on the Event Calendar of ... |
|Primary IR Contact|
CFO and VP, Corporate Development
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.